Balyasny Asset Management
TPST icon

Balyasny Asset Management’s Tempest Therapeutics TPST Stock Holding History

Balyasny Asset Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3
Closed -$98K – 1528
2015
Q4 		$98K Buy
+3
New +$98.9K ﹤0.01% 1165

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management's TPST Position: Q1 2016 in Review

Balyasny Asset Management sold out of Tempest Therapeutics (TPST) in Q1 2016, closing a stake of 3 shares — an estimated $98K sold.

Balyasny Asset Management first reported a position in TPST in Q4 2015 and held it in 1 quarter. The position peaked at $98K in Q4 2015. 73 funds tracked by Wall St. Rank hold TPST as of Q1 2016.

  • Balyasny Asset Management reported no remaining Tempest Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 3 Tempest Therapeutics shares in Q1 2016, an estimated $98K.
  • Balyasny Asset Management first reported a position in Tempest Therapeutics in Q4 2015 and held it in 1 quarter.
  • Balyasny Asset Management's Tempest Therapeutics position peaked at $98K in Q4 2015.
  • 73 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2016.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.